Hemostemix Inc. (CVE:HEM – Get Free Report)’s share price shot up 15% during mid-day trading on Friday . The stock traded as high as C$0.23 and last traded at C$0.23. 506,476 shares traded hands during trading, a decline of 3% from the average session volume of 520,039 shares. The stock had previously closed at C$0.20.
Hemostemix Stock Performance
The firm has a market cap of C$19.17 million, a PE ratio of -11.00 and a beta of 0.20. The stock has a 50 day simple moving average of C$0.09 and a two-hundred day simple moving average of C$0.07.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
See Also
- Five stocks we like better than Hemostemix
- 3 Fintech Stocks With Good 2021 Prospects
- Driving Forward: Lucid’s Growing Sales and Gravity SUV’s Impact
- Most Volatile Stocks, What Investors Need to Know
- Why Amazon’s Next Earnings Could Trigger a Stock Breakout
- Why Are Stock Sectors Important to Successful Investing?
- With This Kind of Data, The Fed Isn’t Cutting Rates This Year
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
